
This review highlights recent advancements in KRAS inhibitor development for NSCLC following the approval of sotorasib and adagrasib. Despite initial success, their efficacy is limited by resistance, prompting research into more potent inhibitors and combination therapies, including novel approaches like molecular shielding and immunological strategies.
Like
Save
Share